Statements of Cash Flows (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment	$ 235,640
Common Stock And Warrants
Payments of stock issuance costs	158,678	$ 1,336,123
Series B Convertible Preferred Stock
Payments of stock issuance costs	$ 0	$ 497,617